Most of what Cramer says on the “Mad Money” Lightning Round is fast and directional. Occasionally, he drops a framework that reveals how he actually thinks about investing, not just trading.
When a caller asked about Eli Lilly (LLY) on Tuesday, July 28, Cramer did not give a buy or sell, according to CNBC. He gave a philosophy.
Eli Lilly is classic own, don’t trade.
“Eli Lilly is a good company, and I’ve owned it for years,” Cramer continued. “I’m going to continue to own it for years because it’s a great business with great drugs.”
That is actually a patience call on LLY, dressed up as an investment thesis.
The 150-year-old pharmaceutical, Eli Lilly (LLY), is trading near $1,154.97 as of this writing, according to Yahoo Finance, down from its July 7 all-time high of $1,249.45.
The stock is up 7.84% year to date and 53.03% over the past year. Over five years, LLY has returned 397.23%, compared to the S&P 500‘s 69.22%.
Cramer has been right about this one for years. The question is whether the thesis still applies at four-digit stock prices.
Also Read: Eli Lilly and Company (LLY) Latest News and Stories
Why Cramer calls LLY “own, don’t trade”: the business case
The “own, don’t trade” framework reflects a specific view about competitive advantage and earnings durability. You own rather than trade when the underlying business compounds in a way that makes short-term price volatility irrelevant to the long-term outcome.
Eli Lilly’s GLP-1 franchise is one of the most remarkable revenue growth stories in pharmaceutical history. Mounjaro and Zepbound have driven the kind of volume acceleration that most drug companies never experience.
More Jim Cramer:
- Jim Cramer’s cryptic comments on key AI supplier turn heads
- Jim Cramer says investors are getting the Mag 7 all wrong
- Jim Cramer recommends buying these 5 stocks
International demand, particularly after Mounjaro’s inclusion in China’s National Reimbursement Drug List, according to Reuters, has added another dimension to what was already a dominant domestic position.
The FDA approval of Foundayo, the orforglipron GLP-1 pill that can be taken any time without food or water restrictions, adds a new product to that franchise.
A pill form of GLP-1 therapy could meaningfully expand the addressable patient population beyond those comfortable with injections. If Foundayo scales, it will significantly extend the runway.
Q1 2026 results, reported April 30, showed what that business looks like.
- Revenue reached $19.8 billion, up 56% year over year.
- EPS on a non-GAAP basis grew 156% to $8.55.
- Full-year 2026 revenue guidance was raised to $82 billion to $85 billion, with non-GAAP EPS guidance of $35.50 to $37.00.
What LLY stock Aug. 5 earnings need to show
Eli Lilly reports Q2 2026 earnings on Aug. 5. The Zacks consensus expects EPS of $6.71, up 6.3% year over year, on revenue of $20.26 billion, up 30.2% year over year, according to Zacks data.
The 30% revenue growth expectation is significant in the context of its Q1. Lilly delivered 56% revenue growth in Q1, so the 30% estimate for Q2 reflects a meaningful deceleration from that pace, primarily because Q2 2025 was already a stronger comparison period than Q1 2025.
Related: Jim Cramer reveals exactly when to buy SpaceX dip
My read of the setup is that the print matters less than the guidance language. What investors will be listening for is any color on Foundayo adoption trajectory, Zepbound supply and pricing updates, and whether the full-year $82 to $85 billion guidance band gets raised again.
Lilly has raised guidance after each of the last several quarters. Another raise would reinforce Cramer’s “own, don’t trade” thesis as a current fact rather than a historical statement.
Houston Chronicle via Getty Images
The LLY manufacturing and pipeline moves that frame the longer-term case
On July 30, Lilly and Resilience announced a $750 million investment to expand U.S. manufacturing capacity, which is expected to create approximately 400 new jobs.
That capital commitment signals management confidence in sustained demand, not a one-cycle phenomenon.
On the pipeline, Q1 brought positive Phase 3 results from Foundayo in type 2 diabetes, Jaypirca in combination therapy for certain blood cancers, and early data supporting Zepbound in combination with Taltz for patients with both psoriasis and obesity.
Four acquisitions were announced in Q1 alone, including Orna Therapeutics, Centessa Pharmaceuticals, Kelonia Therapeutics, and Ajax Therapeutics, suggesting Lilly is actively adding pipeline optionality, rather than relying solely on its current product stack.
Lilly also joined Illumina’s Billion Cell Atlas to leverage AI-driven drug discovery research across an enormous genetic dataset, positioning the company at the intersection of biological research and artificial intelligence.
Cramer’s “I’ve owned it for years, and I’m going to continue to own it for years” is essentially a statement about the compounding of business quality over time.
At $1,154, with a five-year return of 397% and Aug. 5 earnings approaching with another potential guidance raise, the case supporting Cramer’s statement remains relevant and intact.
Related: Goldman Sachs sees writing on the wall for Eli Lilly stock
